Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Randomized, Open-labeled, Positive-controlled, Phase Ⅱ Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.

NCT02005458 is registered in ClinicalTrials.gov with Xiamen Amoytop Biotech Co., Ltd. as lead sponsor.

NCT NCT02005458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02005458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Randomized, Open-labeled, Positive-controlled, Phase Ⅱ Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.
Lead sponsor
Xiamen Amoytop Biotech Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
February 28, 2018
Enrollment
80 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, non small cell lung cancer